Dasatinib Shortage: What Providers and Prescribers Need to Know in 2026

Dasatinib (Sprycel) remains a cornerstone treatment for Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia. While the drug is not in an FDA-declared shortage as of 2026, prescribers in oncology and hematology are contending with system-level access barriers that can delay treatment initiation and disrupt ongoing therapy. This guide provides a practical clinical briefing for providers navigating these challenges.

Current Supply Status: No FDA Shortage, but Systemic Access Barriers Remain

Dasatinib is not listed on the FDA Drug Shortage database as of early 2026. Generic dasatinib is now manufactured by Apotex, Teva, Lupin, Zydus Pharma, Dr. Reddy's, and others under approved NDAs. Brand Sprycel (Bristol-Myers Squibb) continues to be marketed alongside these generics. Supply chain diversification means a true drug-wide shortage is unlikely.

However, patients regularly report delays of 1–4 weeks in obtaining their initial fill—and sometimes experience disruptions in ongoing therapy. The root causes are systemic and administrative rather than supply-based. Understanding these barriers is essential to protecting your patients' access.

Key Access Barriers for Providers to Understand

1. Specialty Pharmacy Mandate: Nearly all commercial and Medicare Part D plans require dasatinib to be dispensed through a designated specialty pharmacy. Prescriptions sent to retail pharmacies or out-of-network specialty pharmacies will be rejected. Your practice should have an up-to-date list of contracted specialty pharmacies for the major payers you encounter.

2. Prior Authorization Requirements: Prior authorization is universally required. Documentation typically includes: Ph+ status confirmed by cytogenetics or FISH/PCR, diagnosis (CML phase or ALL), prior TKI history (if applicable), and rationale for dasatinib vs. alternatives. Consider implementing standardized PA letter templates in your practice to expedite submission.

3. Step Therapy Mandates: Some commercial payers require trial of generic imatinib before approving a second-generation TKI. While all five first-line TKIs carry NCCN Category 1 evidence for newly diagnosed CML-CP, formulary placement varies by plan. If step therapy is required in a clinically inappropriate situation, submit a step therapy exception request with supporting clinical rationale—including disease characteristics, patient comorbidities, or risk stratification (Sokal/EUTOS score) that favor dasatinib.

4. Generic Substitution Considerations: Generic dasatinib tablets (Apotex, Teva, and others) are FDA-approved as therapeutically equivalent to Sprycel. Formulary substitution by payers is increasingly common. For most patients, generic substitution is clinically appropriate. If you have a specific clinical reason to prefer a particular formulation, document it and communicate with the specialty pharmacy proactively.

Clinical Considerations During Access Delays

When a patient experiences a delay in obtaining dasatinib, the clinical approach depends on context:

• Newly diagnosed CML-CP: Short delays of 1–2 weeks are generally manageable. Hydroxyurea can be used briefly in symptomatic patients with markedly elevated white cell counts while awaiting TKI initiation.
• CML advanced phase or Ph+ ALL: Urgency is significantly higher. Escalate prior authorization as urgent/expedited immediately. Contact BMS Access Support or the specialty pharmacy patient services team directly.
• Established patients experiencing refill delays: Consider prescribing a brief medication bridge (if samples are available) and have the care team proactively follow up with the specialty pharmacy rather than waiting for the patient to report non-receipt.

Patient Assistance and Copay Programs Available for Dasatinib

When cost is a barrier, the following programs can help:

• BMS Access Support (Sprycel): Provides copay assistance for commercially insured patients and free medication for uninsured or underinsured patients through the BMS Patient Assistance Foundation. Contact through sprycel.com/financial-support.
• Apotex Dasatinib Instant Savings Card: For commercially insured patients taking generic dasatinib, this program offers $0 copay assistance, covering up to $625 per 30-day supply, up to $7,500 per calendar year. Not available for Medicare/Medicaid patients. Call (833) 415-4368.
• Leukemia & Lymphoma Society (LLS) Co-Pay Assistance: LLS provides disease-specific financial assistance for blood cancer patients, including CML and ALL. Visit lls.org/co-pay for eligibility.

Clinical Alternatives if Dasatinib Remains Inaccessible

If dasatinib truly cannot be obtained for a patient with newly diagnosed CML-CP, the NCCN and ELN 2020 guidelines support substitution with any of the other Category 1 TKIs: imatinib, nilotinib, bosutinib, or asciminib. Selection should be individualized based on comorbidities (cardiovascular risk for nilotinib; GI considerations for bosutinib), mutation profile, and prior therapy. For Ph+ ALL, escalate to institutional hematology protocols and consider clinical trial enrollment if standard access is unresolvable.

How medfinder Supports Your Patients

medfinder offers a provider-facing service at medfinder.com/providers that helps your patients find which pharmacies near them can fill their prescription. When specialty pharmacy routing breaks down, medfinder's direct pharmacy outreach can help identify alternatives quickly—reducing the time your staff spends on hold and keeping patients on therapy.